Popular Trials
Behavioral Intervention
Multidisciplinary Care for Rheumatoid Arthritis
This trial will test a new intervention for socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis to see if it improves remission rates. The intervention is based on a partnership between the patient and the extended healthcare team, and includes things like self-management education and technology-based at-home monitoring of symptoms.
Behavioural Intervention
Family Physician Consultations for Rheumatoid Arthritis
This trial aims to see if adding a family doctor to a team of rheumatologists can help improve the overall health of people with rheumatoid arthritis. The family doctor will focus on vaccinations, heart
Popular Filters
Trials for RA Patients
Behavioral Intervention
Mindfulness Program for Rheumatoid Arthritis
This trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The goals are to assess patient satisfaction, identify barriers to participation, and understand how mindfulness impacts RA symptoms. Participants will
Monoclonal Antibodies
Imvotamab for Rheumatoid Arthritis
This trial tests the safety and tolerability of imvotamab, a new medication, in adults with severe rheumatoid arthritis who haven't responded to other treatments. The study will help understand how the drug works in the body and its effects on inflammation.
Probiotic
Probiotic R-2487 for Rheumatoid Arthritis
This trial is testing a probiotic supplement taken by mouth to see if it is safe and well-tolerated in people with Rheumatoid Arthritis. The goal is to find out if improving gut health can help reduce inflammation and manage symptoms of the disease. Probiotics, including various Lactobacillus species, have been studied for their potential to alleviate symptoms of rheumatoid arthritis by normalizing gut microbiota and reducing inflammation.
Shared Decision Making Intervention for Rheumatoid Arthritis
This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new method of giving Enbrel using the SOFUSA system for RA patients who haven't responded well to usual treatments. The SOFUSA system delivers the drug directly through the skin to improve its effectiveness and reduce side effects. Enbrel was the first biological treatment and the first tumour necrosis factor inhibitor approved for use in rheumatic diseases.
Trials for Osteoarthritis Patients
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Joint Replacement
Nexel Total Elbow Replacement for Elbow Osteoarthritis
This trial aims to confirm the safety and effectiveness of the Zimmer Nexel Total Elbow in patients needing their first or a revised elbow replacement. The device replaces damaged parts of the elbow to help reduce pain and improve function. The Zimmer Nexel Total Elbow is used to replace damaged parts of the elbow, primarily in patients with severe elbow pain and joint destruction.
Phase 3 Trials
Disease-modifying antirheumatic drugs (DMARDs)
DMARDs for Rheumatoid Arthritis
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
This trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Device
Vagus Nerve Stimulation for Rheumatoid Arthritis
This trial will assess the safety and efficacy of a new device designed to treat rheumatoid arthritis by stimulating the vagus nerve. The study will enroll 250 subjects at 40 sites, who will either receive active or non-active stimulation. There will be a one-way crossover of control subjects to active stimulation after 12 weeks, and all subjects will receive active stimulation for the next 180 weeks to evaluate long-term safety.
Trials With No Placebo
Behavioral Intervention
Mindfulness Program for Rheumatoid Arthritis
This trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The goals are to assess patient satisfaction, identify barriers to participation, and understand how mindfulness impacts RA symptoms. Participants will
Probiotic
Probiotic R-2487 for Rheumatoid Arthritis
This trial is testing a probiotic supplement taken by mouth to see if it is safe and well-tolerated in people with Rheumatoid Arthritis. The goal is to find out if improving gut health can help reduce inflammation and manage symptoms of the disease. Probiotics, including various Lactobacillus species, have been studied for their potential to alleviate symptoms of rheumatoid arthritis by normalizing gut microbiota and reducing inflammation.
Shared Decision Making Intervention for Rheumatoid Arthritis
This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new method of giving Enbrel using the SOFUSA system for RA patients who haven't responded well to usual treatments. The SOFUSA system delivers the drug directly through the skin to improve its effectiveness and reduce side effects. Enbrel was the first biological treatment and the first tumour necrosis factor inhibitor approved for use in rheumatic diseases.
Procedure
Ulcer Healing Analysis for Inflammatory Bowel Disease
This trial involves taking small pieces of tissue from the colon to study how ulcers heal. It includes patients with inflammatory bowel disease, arthritis, and healthy individuals to compare healing processes. Researchers will examine how genes work and how cells produce energy to understand healing.
View More Related Trials
Frequently Asked Questions
Introduction to rheumatoid arthritis
What are the top hospitals conducting rheumatoid arthritis research?
When it comes to advancing treatments for rheumatoid arthritis, several hospitals are leading the charge. One such institution is the Altoona Center for Clinical Research in Duncansville, which currently has eight active clinical trials dedicated to this condition and an impressive history of 64 completed trials since their first recorded trial in 2002. In Boston, Brigham and Women's Hospital is making significant strides as well with five ongoing rheumatoid arthritis trials and a total of 21 previously conducted studies dating back to their inaugural trial in 2003. Meanwhile, Desert Medical Advances in Palm Desert contributes its expertise with four active clinical trials and a commendable track record of 33 previous investigations since their initial rheumatoid arthritis trial was documented in 2005.
Additionally, Altoona Center For Clinical Research continues its dedication by conducting four current clinical tests while having accomplished twenty-five researches over years including multiple facets from inception phase itself during that very year they started examining Rheumatoid Arthritis patients.For Physician Research Collaboration LLC located at Lincoln , offering treatment possibilities through participating into their four on-going RA medical examinations;their initiatives so far go back till they registered commencement initiative around fourteen years ago from present time i.e.,in year2007.
These establishments represent the hope and determination found within the medical community when it comes to combating rheumatoid arthritis. By conducting these vital clinical trials, researchers aim not only to alleviate symptoms but also develop groundbreaking therapies that can improve the lives of millions affected by this chronic autoimmune disease worldwide
Which are the best cities for rheumatoid arthritis clinical trials?
When it comes to rheumatoid arthritis clinical trials, several cities are at the forefront of research and development. Houston, Texas leads with 23 active trials focusing on treatments like Baricitinib, Upadacitinib, and Peresolimab. Duncansville, Pennsylvania follows closely behind with 17 ongoing studies investigating options such as KPL-404 and Abatacept. Lastly, Boston, Massachusetts also has 17 active trials exploring interventions including Cohort B and Arm B2P: BNT162b2 along with Nivolumab. These cities offer individuals with rheumatoid arthritis access to cutting-edge clinical trials that open doors for potential breakthroughs in treatment options and improved quality of life.
Which are the top treatments for rheumatoid arthritis being explored in clinical trials?
Exciting developments in rheumatoid arthritis research are underway, with several promising treatments taking center stage in clinical trials. Leading the pack is upadacitinib, currently being explored in two active trials and boasting a total of 15 past studies dedicated to rheumatoid arthritis since its introduction in 2014. Close behind is abatacept, which has caught the attention of researchers with two ongoing trials and an impressive record of 54 all-time clinical trials for this condition since its listing back in 2002. Also making waves is baricitinib, involved in two current investigations and contributing to a cumulative total of 13 previous rheumatoid arthritis studies since its debut in 2007. As these trials progress, new possibilities for treating rheumatoid arthritis may soon become reality.
What are the most recent clinical trials for rheumatoid arthritis?
Exciting developments are underway in the field of rheumatoid arthritis, with several recent clinical trials bringing hope for improved treatment options. One such trial involves VIB4920 in combination with TNFi, showing promise in its Phase 2 study that commenced on September 15th, 2023. Additionally, ANB030 SC Dose 1 and Certolizumab + Nipocalimab have shown potential benefits as well during their respective Phase 2 trials which began on August 31st and August 15th, respectively. Another notable advancement is Upadacitinib's ongoing Phase 3 trial initiated on June 15th, aiming to further validate its efficacy against this debilitating condition. Lastly, LY3871801 has entered a Phase-2a study since May 23rd to investigate its potential benefits for individuals living with rheumatoid arthritis. These promising clinical trials pave the way towards new possibilities of managing and treating this chronic inflammatory disease effectively.
What rheumatoid arthritis clinical trials were recently completed?
Several recent clinical trials have brought significant advancements in the treatment of rheumatoid arthritis. In October 2021, Janssen Research & Development completed two trials for potential therapies: JNJ-67484703 and Nipocalimab. Furthermore, UCB Biopharma SRL wrapped up their Certolizumab pegol trial in February 2021. Other noteworthy completed trials include LY3462817 by Eli Lilly and Company in January 2021, PF-06650833 by Pfizer in July 2020, and branebrutinib sponsored by Bristol-Myers Squibb in January 2020. These studies demonstrate the ongoing efforts to find new therapeutic options for individuals living with rheumatoid arthritis, highlighting a promising future for patients grappling with this challenging condition.